Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARAVAGGIO: Apixaban vs dalteparin for treatment of cancer-associated venous thromboembolism
2016-003093-40Phase 3Completed
- Sponsor
- Fondazione FADOI
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of apixaban in venous thromboembolism (VTE), deep vein thrombosis (DVT), pulmonary embolism (PE) and 1 more (2 arms), sponsored by Fondazione FADOI. Started Dec 2016; status: completed.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)cancer
Beyond the preview
Go deeper on 2016-003093-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003093-40.